Aeolus files patent application for novel developments of AEOL 10150

Aeolus Pharmaceuticals, Inc., announced on Thursday that it filed a provisional application regarding new developments with its lead compound, AEOL 10150, with plans to patent-protect its technologies until 2034.

Aeolus filed its provisional application with the United States Patent and Trademark Office. If granted, the patent would protect novel synthesis technologies, crystal developments and pharmaceutical developments of AEOL 10150 and similar porphyrin developments.

The research and development that lead to the new inventions of AEOL 10150 was a result of working under contract with the Biomedical Advanced Research and Development Authority towards Good Manufacturing Practice production technologies of AEOL 10150. The cost-plus contract is worth $118 million over the course of five years and was awarded in February 2011.

"These new patents, if granted, would substantially increase the life of the patent protection surrounding AEOL 10150," Chief Executive Officer of Aeolus Pharmaceuticals John McManus said. "Extended patent life would open up new potential strategic options for the future development of AEOL 10150 in multiple indications. The work that led to this filing is an excellent example of the value that BARDA brings as a partner in advanced drug development. We are very grateful for both their financial support and their technical input."

Aeolus also has plans to protect its novel inventions and technologies internationally through a subsequent PCT application in 2014. If approved, the novel AEOL 10150 developments would be protected until at least 2034 in many countries.

Organizations in this Story

Aeolus Pharmaceuticals

Want to get notified whenever we write about Aeolus Pharmaceuticals ?
Next time we write about Aeolus Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.